Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab in relapsed/refractory acute lymphoblastic leukemia
Key Points• Multiple mechanisms of acquired CD19 mutations and splicing contribute to CD19 loss and relapse to blinatumomab.• Identification of CD19 ex2part levels represents a new biomarker predictive of resistance or likely failure of blinatumomab
- Type: Other
- Archiver: EGA European Genome-Phenome Archive
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001005729 | Illumina HiSeq 2000 | 56 | |
| EGAD00001005730 | Illumina HiSeq 2000 | 60 | |
| EGAD00001005731 | Illumina HiSeq 2000 | 41 | |
| EGAD00001005732 | Illumina HiSeq 2000 | 10 | |
| EGAD00001005733 | Illumina HiSeq 2000 | 10 |
| Publications | Citations |
|---|---|
|
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Blood 137: 2021 471-484 |
32 |